The deaths of 66 children in this West African country could severely damage India's image as the "pharmacy of the world."
India has announced[/B] that it will test samples of four syrups for cough manufactured and exported by local company Maiden Pharmaceuticals, following the announcement by the World Health Organization that some of its products have been linked to the deaths of dozens of children in The Gambia.
The deaths of 66 children in this West African country could severely damage India's image as the "pharmacy of the world".
Unacceptable quantities
The WHO this week announced that following an analysis of four Maiden syrups - Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup-confirmed "unacceptable" amounts of diethylene glycol and ethylene glycol, which can be toxic and lead to acute kidney injury.
Diethylene glycol and ethylene glycol are used in antifreeze and brake fluids and other industrial applications, but also as a cheaper alternative to glycerol in some pharmaceuticals-a solvent or viscosifying agent (liquid materials become viscous) in many cough syrups.
They are looking for a link between the deaths and the formulations
India's health ministry said samples of all four products exported to The Gambia were sent for testing at a federal laboratory and the results will "guide further action and also clarify the involvement that WHO had or will have".
The ministry has asked the WHO to share the findings of its report "identifying the link between child deaths and the medical formulations in question."
WHO spokeswoman Margaret Harris did not respond to a Reuters request for information on when the report would be sent to the health ministry.
She said, however, that information from Maiden and the director of India's Central Drugs Control Board indicated that authorities had visited the company's factories "to investigate this particular incident and the WHO is awaiting the findings."
Anil Vijay, the health minister of Haryana state where Maiden's factories are located, warned of "serious action if any fault is found" after the tests were conducted.
Investigating child deaths from acute kidney injury
WHO Secretary-General Tedros Adanom Gebrejesus told reporters on Wednesday that the UN agency is investigating child deaths from acute kidney injury in collaboration with India's drug regulator and the pharmaceutical company.
The agency informed India's drug regulator about the deaths late last month and then followed up with state authorities with an investigation alongside that of the WHO.
One of Maiden's directors, Naresh Kumar Goyal, however, told Reuters that the company was only informed of the deaths yesterday morning and was trying to get details.
Maiden, which began operations in November 1990, manufactured and exported the syrup only in The Gambia, according to the health ministry.
The company also exported
On its website, the company says it has two factories - in Kundli and Panipat - both near New Delhi in Haryana state, and recently opened another.
The company has an annual production capacity of 2.2 million syrup bottles, 600 million capsules, 18 million injections, 300,000 tubes of ointment and 1.2 billion pills.
On its website, Maiden says it sells its products domestically but also exports them to countries in Asia, Africa and Latin America although Goyal said they are not currently sold in India.
The health ministry claimed that importing countries normally carry out checks on such products before allowing their use.
APE-MPA
Contents of this article including associated images are belongs to Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times
Source[/URL]